Unilife Appoints Harry Hamill to the Board of Directors

http://www.marketwatch.com/story/unilife-appoints-harry-hamill-to-the-board-of-directors-2015-08-25

YORK, Pa., Aug. 25, 2015 /PRNewswire/ -- Unilife Corporation ("Unilife" or the "Company") , a developer, manufacturer and supplier of injectable drug delivery systems, today announced the appointment of Mr. Harry Hamill to the Board of Directors, the appointment of Ms. Mary Kate Wold as Lead Independent Director, and the retirement of Mr. Jim Bosnjak after 12 years of service.
Mr. Hamill, 61, is a seasoned financial executive in the public company life sciences sector, who prior to his retirement held several senior finance positions at Wyeth.  During Mr. Hamill's 18-year career at Wyeth, he held various executive roles, including leading global Mergers and Acquisitions, Vice-President of Finance for Wyeth's global manufacturing and distribution operations, CFO of a global animal health business unit, and Corporate Vice President and Deputy Controller.  Prior to his career at Wyeth, Mr. Hamill was a Partner at a large regional public accounting firm.  He is a Certified Public Accountant and a graduate of Baruch College.  
Mr. Alan Shortall, Chairman and CEO of Unilife said: "It is with great pleasure that I welcome Harry Hamill to our Board of Directors.   Harry brings a strong combination of finance, operations and M&A experience in the life sciences industry to Unilife, and I expect he will provide seasoned and wise leadership to the Company."
Appointment of Mary Kate Wold as Lead Independent Director
Ms. Mary Kate Wold, who joined the Unilife Board in 2010 and is Chief Executive Officer of the Church Pension Fund, has been appointed as Vice Chair and Lead Independent Director. She will also continue to serve as Chair of the Strategic Partnerships Committee and as a member of the Audit Committee and Nominating and Governance Committee.
Mr. Shortall said: "Mary Kate Wold has provided Unilife with strong and independent counsel since her appointment to our Board as a Director in 2010. With her appointment as Lead Independent Director, I expect her contributions to Unilife will become even more valuable moving forward."
Retirement of Jim Bosnjak
Mr. Jim Bosnjak, 66, has advised Unilife of his decision to retire from the Board for health reasons. Mr Bosnjak was first appointed to the Unilife Board in 2003 and served as Chairman between 2006 and 2013. Mr. Bosnjak will continue to serve as a strategic advisor to the Board as his health permits.
Mr. Alan Shortall said: "Jim has been a wonderful supporter of Unilife for more than a decade.  As a former Chairman and long-term member of our Board, Jim has made significant contributions towards our growth and expansion. On behalf of the Board and management team of Unilife, I thank Jim for his service and wish him a speedy recovery. I also look forward to Jim's continued counsel to me and the Board as his health and time allow."